The company said its total revenue for Q3 2024 rose 7% year over year to $7.5 billion. Product sales excluding Veklury increased 7% to $6.8 billion, and HIV product sales rose 9% to $5.1 billion.

1. 01

   The company said its total revenue for Q3 2024 rose 7% year over year to $7.5 billion. Product sales excluding Veklury increased 7% to $6.8 billion, and HIV product sales rose 9% to $5.1 billion.

2. 02

   Gilead said its diluted EPS for Q3 2024 was $1.00, down from $1.73 in the same period of 2020. The company cited an in-process research and development (IPR&D) impairment of $1.75 billion ($1.04 per share net of tax) related to assets acquired from Immunomedics, as well as higher acquired IPR&D expense, as factors behind the decline.

3. 03

   Gilead said it generated operating cash flow of $4.3 billion in Q3 2024, paid dividends of $983 million and repurchased $300 million of common stock. As of September 30, 2024, its cash, cash equivalents and marketable debt securities totaled $5.0 billion, down from $8.4 billion as of December 31, 2023.

4. 04

   The company set its full-year 2024 product sales outlook at $27,800 million to $28,100 million, versus its prior outlook of $27,100 million to $27,500 million. Its non-GAAP diluted EPS outlook is $4.25 to $4.45, compared with the prior outlook of $3.60 to $3.90.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.